Pecs

• Master Protocol for Encorafenib/Binimetinib Continuation Sub-Studies (FLOTILLA Study) Ended recruitment
  2023-509408-13-00 6 2022-09-20 Solid tumors
• A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients with Multiple Sclerosis Ended recruitment
  2023-505974-14-00 5 2022-06-23 Multiple Sclerosis (MS)
• A phase III, randomized, double-masked, placebo-controlled, parallel-group, multicenter study of the safety and efficacy of OT-101 (Atropine … Ended recruitment
  2024-516315-24-00 5 2022-05-27 myopia
• A Placebo-Controlled Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease … Ended recruitment
  2023-507795-51-00 5 2022-05-17 atherosclerotic heart and blood vessel disease (the narrowing of arter
• Phase 3 Study of Anifrolumab in Adult Patients with Active Proliferative Lupus Nephritis Ended recruitment
  2023-506359-68-00 5 2022-04-08 Active Proliferative Lupus Nephritis
• A study of lurbinectedin in combination with atezolizumab compared with atezolizumab as maintenance therapy in participants with extensive-s … Ended recruitment
  2023-503868-16-00 5 2022-02-14 Small-Cell Lung Cancer (SCLC)
• A study to learn how well finerenone works; how safe it is; how it moves into, through, and out of the body; and the effects it has on the b … Ended recruitment
  2023-504884-17-00 5 2022-02-04 Proteinuria
• A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people … Ended recruitment
  2024-510735-21-00 5 2021-11-26 Atherosclerotic cardiovascular disease (ASCVD)
• A rollover extension program (REP) to evaluate the long-term safety and tolerability of open label iptacopan in adult participants with prim … Ended recruitment
  2023-508690-92-00 11 2021-09-20 IgA Nephropathy
• The STARBOARD Study: Phase 3 Study of Encorafenib and Binimetinib Plus Pembrolizumab in BRAF V600E/K Mutation-Positive Metastatic or Unresec … Ended recruitment
  2024-512038-13-00 5 2021-09-16 Metastatic or unresectable locally advanced BRAF V600E/K mutation posi
• Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic … Ended recruitment
  2023-506752-24-00 5 2021-08-05 Locally recurrent inoperable or metastatic HR+/HER2- breast cancer, wh
• A Multi Arm Study in Participants with MSI-High Metastatic Colorectal Cancer Ended recruitment
  2022-502100-70-00 10 2021-06-23 Participants with Microsatellite Instability-High (MSI-H) or Mismatch
• A Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in R/R DLBCL Ended recruitment
  2023-504830-23-00 5 2020-12-16 B-cell Lymphoma
• A Phase 3 study to compare long-term efficacy and safety of macitentan 75 mg versus 10 mg in Pulmonary Arterial Hypertension. Ended recruitment
  2024-515669-32-00 5 2020-06-30 Pulmonary arterial hypertension
• A study investigating the long-term safety and efficacy of intravenous (IV) ATB200 when Co-administrated with oral AT2221 in adult subjects … Ended recruitment
  2023-505170-15-00 5 2020-05-15 Adult Subjects With Late Onset Pompe Disease (LOPD)
• A trial to learn how camizestrant (AZD9833) works compared to fulvestrant and how safe it is in women with advanced breast cancer who have g … Ended recruitment
  2023-504974-40-00 4 2020-04-24 Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer
• A multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients wit … Ended recruitment
  2023-508292-37-00 5 2020-03-06 Cardiovascular Disease
• A Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherap … Ended recruitment
  2022-501531-16-00 5 2020-01-24 esophageal carcinoma
• A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant trea … Ended recruitment
  2023-510357-42-00 5 2019-05-22 hormone receptor (HR)-positive, HER2-negative, early breast cancer (EB
• An open-label extension (OLE) study to evaluate the long-term safety and efficacy of ralinepag in patients with pulmonary arterial hypertens … Ended recruitment
  2023-509305-68-00 5 2019-05-16 Pulmonary arterial hypertension (PAH)
• TALAPRO 2: A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT … Ended recruitment
  2023-509087-20-00 5 2019-04-16 Metastatic Castration-resistant Prostate Cancer
• An open-label extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with RMS Ended recruitment
  2023-507906-15-00 5 2019-01-30 Relapsing multiple sclerosis (RMS)
• Evaluation of Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Patients with Moderate to Severe Atopic Derma … Ended recruitment
  2022-502937-24-00 5 2019-01-02 Atopic Dermatitis
• Phase III study of pembrolizumab for high-risk early-stage ER+/HER2– breast cancer Ended recruitment
  2023-506921-12-00 5 2018-12-27 ER+/HER2- Breast Cancer

Showing 193–216 of 314 trials